Therefore, based on the mEGOS score, we combined ALB, FPG, NLR, PLR, and other routine clinical testing parameters to predict the adverse outcome of GBS and established a new prognostic prediction model—mEGOS-I—which showed better predictive power than the mEGOS score. This evidence concerns the gene ALB and Guillain-Barre syndrome.